| Bone Marrow Diseases |
NCT02480634: Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 280 | NA | Zoledronic acid, Zometa, Radiotherapy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-small Cell Lung Cancer, Bone Metastasis | 09/21 | 12/22 | | |
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase) |
|
|
| Active, not recruiting | 3 | 90 | Japan, US, Europe, RoW | Nilotinib, Imatinib | Novartis Pharmaceuticals | Myelogenous Leukemia, Chronic | 10/18 | 10/18 | | |
|
FAST, NCT02611973: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia |
|
|
| Recruiting | 3 | 2250 | Europe | Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm, Hydroxyurea treatment (HU) | Assistance Publique - Hôpitaux de Paris | MPN, Essential Thrombocythemia | 11/19 | 11/22 | | |
| Recruiting | 2/3 | 116 | Europe | Eltrombopag, Experimental arm, Placebo (for Eltrombopag), control | B. Höchsmann | Anemia, Aplastic | 09/22 | 09/23 | | |
NCT02188706: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) |
|
|
| Active, not recruiting | 2 | 120 | US | Decitabine, Dacogen, Carboplatin, Paraplatin, Arsenic Trioxide, ATO, Trisenox | M.D. Anderson Cancer Center, TEVA, Leukemia SPORE | Leukemia | 07/26 | 07/26 | | |
NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders |
|
|
| Active, not recruiting | 1/2 | | US | tipifarnib | Stanford University, National Cancer Institute (NCI) | Leukemia, Myelodysplastic/Myeloproliferative Neoplasms | | | | |
| No Longer Available | N/A | | US, Canada, Europe, RoW | AMN107 | Novartis Pharmaceuticals | Chronic Myeloid Leukemia | 11/08 | | | |
NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant |
|
|
| No Longer Available | N/A | | Canada | nilotinib | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia | | | | |
NCT01026376: An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) |
|
|
| No Longer Available | N/A | | RoW | decitabine | Janssen-Cilag Farmaceutica Ltda., Janssen Korea, Ltd., Korea | Myelodysplastic Syndromes | 11/11 | 11/11 | | |
| No Longer Available | N/A | | US | Ponatinib, AP24534 | OHSU Knight Cancer Institute, Ariad Pharmaceuticals | Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia | | | | |
NCT01995305: Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents |
|
|
| Available | N/A | | RoW | human whole exome, whole genomic, whole exome | Xiaofan Zhu | Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease, Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases., Hematopoiesis Maintainance. | | | | |
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
HEMATO-BIO, NCT02320656: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders--IPC-2013-015 |
|
|
| Recruiting | N/A | 650 | Europe | Blood sampling, Bone marrow aspirate, Skin biopsy, Buccal swab | Institut Paoli-Calmettes | Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders | 05/19 | 05/24 | | |
| Recruiting | N/A | 750 | US | | Cystinosis Research Foundation | Cystinosis, Nephropathic Cystinosis, Renal Fanconi Syndrome | 12/20 | 12/22 | | |
| Recruiting | N/A | 500 | RoW | | Hospital Israelita Albert Einstein, Hospital Santa Marcelina, Instituto Nacional de Cancer, Brazil, Federal University of Minas Gerais, Irmandade da Santa Casa de Misericordia de Sao Paulo, Federal University of São Paulo | Hematologic Diseases | 12/22 | 04/25 | | |
NCT02330692: Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome |
|
|
| Recruiting | N/A | 1000 | RoW | No intervention | Yonsei University | Myelodysplastic Syndrome | 07/23 | 09/23 | | |
NCT02869256: Regional Central Database Recording of Chronic Myeloid Leukemia |
|
|
| Recruiting | N/A | 400 | Europe | Practices evaluation | Institut Bergonié | Chronic Myeloid Leukemia | 01/24 | 01/24 | | |